Sitemap
- Home
- About Us
- Your Health
- Science & Innovation
- Our responsibility
- Careers
- Investors
-
Media
-
Press releases
-
2023
- Press Release: NEJM publishes once-weekly efanesoctocog alfa Phase 3 data demonstrating its potential to transform the treatment landscape for people with hemophilia A
- Press Release: Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis
- Press Release: Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis
- Press Release : Strong sales performance and double digit EPS growth marking the achievement of the 2022 profitability milestone
-
2022
-
2021
-
2020
-
2019
-
2018
-
2023
- Articles
- Contacts
- Media Alert
-
Press releases
-
Paris 2024 Partnership